NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model

Oncology Reports

Volumn 7, Issue 1, 2000, Pages 151-155

  Nielsen, Loretta L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Breast cancer; Dexamethasone; NK cells; p53 adenovirus; p53 gene therapy; p53 tumor suppressor gene; Recombinant adenovirus; SCH58500; Scid mice; Scid bcige mice

Indexed keywords

DEXAMETHASONE;

ADENOVIRUS; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; FEMALE; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; MOUSE; MOUSE MUTANT; NATURAL KILLER CELL; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; DEXAMETHASONE; FEMALE; GENE THERAPY; GENES, P53; HUMANS; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033630747     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.1.151     Document Type: Article

References (24)

1. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ and Shabram P: Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Human Gene Ther 6: 1403-1416, 1995.
2. Yang Y, Nunes F, Berencsi K, Furth EE, Gönczöl E and Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411, 1994.
3. Wilson C and Kay MA: Immunomodulation to enhance gene therapy. Nat Med 4: 887-889, 1995.
4. Bosma MJ and Carrol AM: The scid mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 9: 323-350, 1991.
5. Dorshkind K, Pollack SB, Bosma MJ and Phillips RA: Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 134: 3798-3801, 1985.
6. Roder J and Duwe A: The beige mutation in the mouse selectively impairs natural killer cell function. Nature 278: 451-453, 1979.
7. Mosier DE, Stell K, Gulizia RJ, Torbett BE and Gilmore GL: Homozygous scid/scid: beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med 177: 191-194, 1993.
8. MacDougall JR, Croy BA, Chapeau C and Clark DA: Demonstration of a splenic cytotoxic effector cell in mice of genotype scid/scid.bg/bg. Cell Immunol 130: 106-117, 1990.
9. Whiteside YL and Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7: 704-710, 1995.
10. Naume B and Espevik T: Immunoregulatory effects of cytokines on natural killer cells. Scand J Immunol 40: 128-134, 1994.
11. Trinchieri G: Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol 7: 83-88, 1995.
12. Wills KN, Maneval DC, Menzel P, et al: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5: 1079-1088, 1994.
13. Anderson SC, Johnson DE, Harris MP, et al: p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 4: 1649-1659, 1998.
14. Gurnani M, Lipari P, Dell J, Shi B and Nielsen LL: Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharm 44: 143-151, 1999.
15. Nielsen LL and Maneval DC: p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5: 52-63, 1998.
16. Nielsen LL, Gurnani M, Syed J, Dell J, Hartman B, Cartwright M and Johnson RC: Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in mouse tumor xenograft models. Hum Gene Ther 9: 681-694, 1998.
17. Nielsen LL, Lipari P, Dell J, Gurnani M and Hajian G: Adeno-virus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4: 835-846, 1998.
18. Adesanya MR, Redman RS, Baum BJ and O'Connell BC: Immediate inflammatory response to adenovirus-mediated gene transfer in rat salivary glands. Hum Gene Ther 7: 1085-1093, 1996.
19. Otake K, Ennist DL, Harrod K and Trapnell BC: Non-specific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 9: 2207-2222, 1998.
20. Zsengeller ZK, Wert SE, Hull WM, Hu X, Yei S, Trapnell BC and Whitsett JA: Persistence of replication-deficient adeno-virus-mediated gene transfer in lungs of immune-deficient (nu/hu) mice. Hum Gene-Ther 6: 457-467, 1995.
21. Musco ML, Cui S, Small D, Nodelman M, Sugarman B and Grace M: A comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy. Cytometry 33: 290-296, 1998.
22. Luna LG: Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. McGraw Hill Book Co., New York, 1968.
23. Hall SJ, Sanford MA, Atkinson G and Chen SH: Induction of potent antitumor natural killer cell activity by herpes, simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 58: 3221-3225, 1998.
24. Mastrangeli A, O'Connell B, Aladib W, Fox PC, Baum BJ and Crystal RG: Direct in vivo adenovirus-mediated gene transfer to salivary glands. Am J Physiol 266: G1146-G1155, 1994.